Neotract raises $23.7M to treat urological and gynecological disorders
Neotract, maker of devices used to treat urological and gynecological disorders, has raised $23.73 million of a targeted $25.2 million second round of funding according to PE Hub. Based in Pleasanton, Calif., the company was backed in this round by Johnson & Johnson Development Corp. and New Enterprise Associates.
Next Story: Oh great. Hackers can take over your iPhone with a text message
Previous Story: Pain treatment maker TorreyPines saved by Raptor merger
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
